Skip to main content

Table 3 Baseline variables predictive of WPAI:SHP subscales at 6 and 12 months in 1747 RA patients

From: Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients

Predictor

Odds ratio (95% CI)

 Outcome: absenteeism

  Fatigue

1.23 (1.02 to 1.49)

  Age (years)

1.20 (1.00 to 1.44)

  CRP

0.82 (0.68 to 0.98)

  % work time missed due to RA (> 0 vs 0)

4.75 (3.35 to 6.75)

  Visit 12 months vs 6 months

1.10 (0.83 to 1.46)

Predictor

Standardized beta-coefficient (β) (95% CI)

 Outcome: presenteeism

  Fatigue

3.44 (2.17 to 4.71)

  Age (years)

1.44 (0.26 to 2.63)

  % impairment while working due to RA

9.36 (7.96 to 10.76)

  % impairment at 12 months vs % impairment at 6 months

−1.98 (−3.39 to −0.58)

  Visit 12 months vs 6 months

−1.16 (−2.57 to 0.24)

 Outcome: Work productivity loss

  Fatigue

4.16 (2.47 to 5.85)

  % overall work impairment due to RA

9.43 (7.74 to 11.12)

  Visit 12 months vs 6 months

−0.60 (−2.64 to 1.44)

 Outcome: Activity impairment

  Fatigue

1.52 (0.79 to 2.26)

  Male vs female

−1.83 (−3.33 to −0.33)

  Age (years)

3.25 (2.61 to 3.90)

  % activity impairment due to RA

9.41 (8.59 to 10.23)

  % activity impairment at 12 months vs % activity impairment at 6 months

−1.92 (−2.67 to −1.18)

  Anxiety/depression

Some vs none

2.80 (1.40 to 4.20)

Extreme vs none

5.81 (2.82 to 8.79)

  Visit 12 months vs 6 months

−2.36 (−3.10 to −1.61)

  1. CI, confidence interval; CRP, C-reactive protein; RA, rheumatoid arthritis; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems